GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

New drug for diabetes and obesity shows promising results

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University. (Read more on the Website of Karolinska Institutet)